Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Prevalence of Lung Cancer in Patients With Interstitial Lung Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02501668
Recruitment Status : Completed
First Posted : July 17, 2015
Last Update Posted : July 17, 2015
Sponsor:
Information provided by (Responsible Party):
Won-Il Choi, Keimyung University Dongsan Medical Center

Brief Summary:
The investigators will evaluate the prevalence of lung cancer associated with interstitial lung disease (ILD) and idiopathic pulmonary fibrosis (IPF) utilizing the Korean Health Insurance Review and Assessment Service (HIRA) database, spanning the period from January 2011 to December 2011. The database (HIRA-NPS-2011-0001) was based on random sampling of outpatients from whole population. Patients with ILDs, IPF, connective tissue disorder (CTD), and COPD were identified based on the International Classification of Disease-10 (ICD-10) diagnostic codes.

Condition or disease
Lung Diseases, Interstitial Lung Cancer

Detailed Description:

The epidemiology of lung cancer related to interstitial lung disease (ILD) with or without with connective tissue disease (CTD) as well as idiopathic pulmonary fibrosis (IPF) has not been well established yet. Interstitial lung disease has a potential to develop lung cancer in the name of scar cancer. The investigators aimed to explore prevalence of lung cancer in patients with ILD with or without CTD and IPF in comparison with chronic obstructive pulmonary disorder (COPD).

The investigators will evaluate the prevalence of lung cancer associated with ILD and IPF utilizing the Korean Health Insurance Review and Assessment Service (HIRA) database, spanning the period from January 2011 to December 2011. The database (HIRA-NPS-2011-0001) was based on random sampling of outpatients from whole population. The sample cases are total 1,375,842. Among them 670,258 cases (age > 40) were evaluated. Patients with ILDs, IPF, CTD, and COPD will be identified based on the International Classification of Disease-10 (ICD-10) diagnostic codes.

Layout table for study information
Study Type : Observational
Actual Enrollment : 1375842 participants
Observational Model: Case Control
Time Perspective: Retrospective
Official Title: The Prevalence of Lung Cancer in Patients With Interstitial Lung Disease
Study Start Date : July 2015
Actual Primary Completion Date : July 2015
Actual Study Completion Date : July 2015

Resource links provided by the National Library of Medicine


Group/Cohort
Lung cancer in population
Lung cancer cases in sample population (670,258 cases)
COPD in population
COPD cases (670,258 cases)
COPD with lung cancer
Lung cancer in COPD
ILD without IPF
Interstitial lung disease (ILD) cases without idiopathic pulmonary fibrosis (IPF)
ILD with lung cancer
Lung cancer cases in ILD
Idiopathic pulmonary fibrosis
Idiopathic pulmonary fibrosis cases
IPF with lung cancer
Lung cancer cases in IPF patients
Connective tissue disorder with ILD
CTD with ILD cases
CTD ILD with lung cancer
Lung cancer cases in CTD with ILD
CTD without ILD
CTD with ILD cases in sample population
CTD without ILD with lung cancer
Lung cancer in CTD without ILD



Primary Outcome Measures :
  1. Lung cancer prevalence [ Time Frame: Up to 12 months ]
    Lung cancer prevalence in different groups



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   40 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

This is a retrospective cohort study based on data collected from the HIRA national database. HIRA is a government-affiliated organization that builds an accurate claims review and is a quality assessment system for the National Health Insurance (NHI). The NHI is the only public medical insurance system operated by the Ministry of Health and Welfare in Korea.

Korean Health Insurance Review and Assessment Service (HIRA) provided sample database, spanning the period from January 2011 to December 2011. The database (HIRA-NPS-2011-0001) was based on random sampling of outpatients from whole population. The sample cases are total 1,375,842. Among them 670,258 cases (age > 40) were evaluated.

Criteria

Inclusion Criteria:

  • equal to above 40 years old

Exclusion Criteria:

  • none

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02501668


Sponsors and Collaborators
Keimyung University Dongsan Medical Center
Investigators
Layout table for investigator information
Principal Investigator: Won-Il Choi, MD Keimyung Unversity Dongsan Medical Center
Layout table for additonal information
Responsible Party: Won-Il Choi, Assoicate Professor, Keimyung University Dongsan Medical Center
ClinicalTrials.gov Identifier: NCT02501668    
Other Study ID Numbers: 2015-05-005
First Posted: July 17, 2015    Key Record Dates
Last Update Posted: July 17, 2015
Last Verified: July 2015
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Lung Diseases
Lung Diseases, Interstitial
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Respiratory Tract Diseases